• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by AcelRx Pharmaceuticals Inc.

    7/31/23 7:50:41 PM ET
    $ACRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRX alert in real time by email
    SC 13G 1 sc13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     



     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.   )*
     

     
    AcelRx Pharmaceuticals, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.001 per share
     
     
    (Title of Class of Securities)
     

     
    00444T209
     
     
    (CUSIP Number)
     

     
    July 20, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [ ]
    Rule 13d-1(b)
     
    [x]
    Rule 13d-1(c)
     
    [ ]
    Rule 13d-1(d)
     





    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Fund II LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power

    1,102,944
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    1,102,944
    8  Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,102,944(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    6.5%
    12
    Type of Reporting Person (See Instructions)

    PN
    (1) The reporting person’s ownership consists of (i) 367,648 shares of common stock, (ii) 367,648 warrants to purchase shares of common stock (“A Warrants”), and (iii) 367,648 warrants to purchase shares of common stock (“B Warrants,” and together with the A Warrants, the “Warrants”).
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Partners II LLC

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    1,102,944
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    1,102,944
    8  Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,102,944(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    6.5%
    12
    Type of Reporting Person (See Instructions)

    OO
    (1) The reporting person’s ownership consists of (i) 367,648 shares of common stock, (ii) 367,648 A Warrants, and (iii) 367,648 B Warrants.


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    1,102,944
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    1,102,944
    8  Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,102,944(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    6.5%
    12
    Type of Reporting Person (See Instructions)
     
    IN
    (1) The reporting person’s ownership consists of (i) 367,648 shares of common stock, (ii) 367,648 A Warrants, and (iii) 367,648 B Warrants.
     

    Item 1.
     
     
    (a)
    Name of Issuer
       
     
    AcelRx Pharmaceuticals, Inc.
     
     
    (b)
    Address of Issuer’s Principal Executive Offices
       
     
    25821 Industrial Boulevard, Suite 400
    Hayward, California 94545
     
     

    Item 2.
     
     
    (a)
    Name of Person Filing
       
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •     Lind Global Fund II LP, a Delaware limited partnership;
    •     Lind Global Partners II LLC, a Delaware limited liability company; and
    •     Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
     
    (b)
    Address of Principal Business Office or, if none, Residence
       
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
     
    (c)
    Citizenship
       
     
    See Row 4 of cover page for each Reporting Person.
     
     
    (d)
    Title of Class of Securities
         
       
    Common Stock, par value $0.001 per share
         
     
    (e)
    CUSIP Number
       
     
    00444T209


    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
    Not applicable.
     
    Item 4.
    Ownership
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
     
    (a)
    Amount Beneficially Owned
       
     
     See Row 9 of cover page for each Reporting Person.
     
     
    (b)
    Percent of Class
       
     
    See Row 11 of cover page for each Reporting Person.
     

     
    (c)
    Number of shares as to which such person has:
     
       
    (i)
    sole power to vote or to direct the vote
         

    See Row 5 of cover page for each Reporting Person.
     
       
    (ii)
    shared power to vote or to direct the vote
         
     
    See Row 6 of cover page for each Reporting Person.
     
       
    (iii)
    sole power to dispose or to direct the disposition of
         

    See Row 7 of cover page for each Reporting Person.
     
       
    (iv)
    shared power to dispose or to direct the disposition of
         
     
    See Row 8 of cover page for each Reporting Person.
     

     
    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
     

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
     
    Not applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable.
     
    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
     
    99.1
    Joint Filing Agreement by and among the Reporting Persons.
     


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    July 31, 2023
     
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton


    Get the next $ACRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ACRX

    DatePrice TargetRatingAnalyst
    8/17/2021$7.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ACRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on AcelRx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of AcelRx Pharmaceuticals with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      8/17/21 6:22:04 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AcelRx Announces Rebranding With Name Change to Talphera, Inc.

      Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on Nasdaq under the trading symbol "TLPH" effective January 10 SAN MATEO, Calif., Jan. 9, 2024 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the rebranding of the Company, with a name change to Talphera, Inc. ("Talphera"). The rebrand decision was made to reflect the Company's strategy of developing and commercializin

      1/9/24 9:05:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States

      Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonstrate challenges physicians have with heparin and citrate, the two currently available CRRT anticoagulants  SAN MATEO, Calif., Dec. 12, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a quantitative market research study evaluating current U.S. physician anticoagulation use during continuous renal replacement therapy (CRRT) in patients with acute kidney injury in the intensive care unit.  Th

      12/12/23 8:30:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

       Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study with pre-agreed upon endpoints planned to initiate in Q4 2023 with topline data expected mid-2024; clinical site readiness is currently underway Niyad would be the first and only approved regional anticoagulant in the U.S. for the extracorporeal circuit, if approved by the FDA SAN MATEO, Calif., Oct. 3, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, t

      10/3/23 8:30:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Angotti Vincent J. bought $7,268 worth of shares (10,000 units at $0.73), increasing direct ownership by 11% to 101,805 units (SEC Form 4)

      4 - ACELRX PHARMACEUTICALS INC (0001427925) (Issuer)

      12/14/23 8:11:04 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dasu Badri N covered exercise/tax liability with 1,618 shares, decreasing direct ownership by 9% to 17,153 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      2/13/24 9:46:15 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palmer Pamela P covered exercise/tax liability with 1,602 shares, decreasing direct ownership by 4% to 35,344 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      2/13/24 9:44:54 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Asadorian Raffi covered exercise/tax liability with 1,790 shares, decreasing direct ownership by 8% to 20,291 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      2/13/24 9:42:43 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    SEC Filings

    See more
    • SEC Form EFFECT filed by AcelRx Pharmaceuticals Inc.

      EFFECT - TALPHERA, INC. (0001427925) (Filer)

      2/14/24 12:15:23 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B7 filed by AcelRx Pharmaceuticals Inc.

      424B7 - TALPHERA, INC. (0001427925) (Filer)

      2/13/24 4:27:26 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by AcelRx Pharmaceuticals Inc.

      S-3 - TALPHERA, INC. (0001427925) (Filer)

      2/6/24 4:44:41 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Financials

    Live finance-specific insights

    See more
    • AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

      Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authorization (EUA) of Niyad™ submitted to the FDA in April; registrational study set to initiate in Q4 2023 Proforma $17.4 million in cash as of June 30, 2023, including gross proceeds from financing closed in July 2023 Senior debt with Oxford fully repaid in Q2 2023 Webcast and conference call to be held today at 4:30 p.m. EDT SAN MATEO, Calif., Aug. 10, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commer

      8/10/23 4:05:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

      HAYWARD, Calif., July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2023 financial results after market close on Thursday, August 10, 2023, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company's business.   Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.acelrx.com and cl

      7/27/23 4:05:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 Webcast and conference call to be held today at 4:30 p.m. EDT HAYWARD, Calif., May 10, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2023 financial results and provided a corporate update. "We have embarked on a new AcelRx chapter by closing the DSUVIA transaction and submitting the request for a

      5/10/23 4:05:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Leadership Updates

    Live Leadership Updates

    See more
    • AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors

      HAYWARD, Calif., Nov. 23, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Jill Broadfoot to the company's Board of Directors. Ms. Broadfoot currently serves as the Chief Financial Officer (CFO) of aTyr Pharma, Inc., a position she has held since July 2018. Prior to joining aTyr, Ms. Broadfoot served as CFO of Emerald Health Pharmaceuticals and Emerald Health Bioceuticals, where she was responsible for establishing operations for the U.S.-based pharmaceutical and bioceutical entities as well as

      11/23/21 5:09:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors

      SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company's board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. Richard Williams, Chairman of the Board, commented: "We are pleased to welcome Dr. Desai to the Board and look forward to working with her to pursue long-term value creation. Her substantial expertise in international pharmaceutical licensing, combined with her background in drug development and commercialization will help us refine corporate strategy to maximize our product pipeline. I

      10/4/21 7:30:00 AM ET
      $ACRX
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors

      REDWOOD CITY, Calif., March 31, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Marina Bozilenko as an independent member of the company's Board of Directors. Ms. Bozilenko has over 30 years of investment banking and other healthcare industry experience, including raising more than $30 billion in capital and executing numerous M&A transactions. She currently serves as a strategic advisor to William Blair & Company, a firm she joined in 2010 as head of biotech & pharma and managing director.

      3/31/21 8:30:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - TALPHERA, INC. (0001427925) (Subject)

      2/14/24 2:58:44 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - TALPHERA, INC. (0001427925) (Subject)

      2/13/24 8:00:48 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by AcelRx Pharmaceuticals Inc.

      SC 13D - TALPHERA, INC. (0001427925) (Subject)

      1/22/24 6:46:08 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care